癌症合并缺血性卒中:血液学与栓塞生物标志物及临床结局
研究前瞻性纳入50例活动性实体瘤合并急性缺血性卒中成人患者,于卒中后72-120小时检测血液学与栓塞生物标志物并随访。中位随访48天,43例(86%)发生复发性血栓栓塞或死亡,D-二聚体、P-选择素、sICAM-1、sVCAM-1及微栓子与主要结局相关。
要点
- 癌症合并急性缺血性卒中患者中,高凝与栓塞标志物可能与非良好临床结局相关。
- 未校正分析中,D-二聚体、P-选择素、sICAM-1、sVCAM-1和微栓子与主要结局相关。
- D-二聚体是唯一与复发性缺血性卒中相关的标志物(HR 1.2;95% CI 1.0-1.5)。
核心结论
- 高凝状态和栓塞性疾病的标志物可能与癌症相关卒中患者的不良临床结局相关。
研究设计与样本
- 前瞻性队列研究,纳入50例活动性实体瘤合并急性缺血性卒中的成人患者,来自两家医院,时间为2016年至2020年。
- 卒中发病后72-120小时采集血液,并进行30分钟经颅多普勒(TCD)微栓子检测。
- 暴露变量为凝血标志物(D-二聚体、凝血酶-抗凝血酶)、血小板标志物(P-选择素)、内皮活化标志物(血栓调节蛋白、可溶性细胞间黏附分子-1 [sICAM-1]、可溶性血管细胞黏附分子-1 [sVCAM-1])以及TCD微栓子的存在。
- 主要结局为复发性动脉/静脉血栓栓塞或死亡的复合终点,采用Cox回归评估生物标志物与后续结局的关联。
主要发现
- 在中位随访时间48天(IQR,18-312)内,43例(86%)参与者发生复发性血栓栓塞或死亡,其中28例(56%)发生复发性血栓栓塞,包括13例复发性缺血性卒中(26%)。
- 未校正分析中,D-二聚体(HR 1.6;95% CI 1.2-2.0)、P-选择素(HR 1.9;95% CI 1.4-2.7)、sICAM-1(HR 2.2;95% CI 1.6-3.1)、sVCAM-1(HR 1.6;95% CI 1.2-2.1)和微栓子(HR 2.2;95% CI 1.1-4.5)与主要结局相关,而凝血酶-抗凝血酶和血栓调节蛋白无关联。
- D-二聚体是唯一与复发性缺血性卒中相关的标志物(HR 1.2;95% CI 1.0-1.5)。
- 校正重要预后变量后,分析结果总体一致。
关键数值与推荐
- 未校正分析中D-二聚体与主要结局的HR为1.6(95% CI 1.2-2.0);P-选择素HR为1.9(95% CI 1.4-2.7);sICAM-1 HR为2.2(95% CI 1.6-3.1);sVCAM-1 HR为1.6(95% CI 1.2-2.1);微栓子HR为2.2(95% CI 1.1-4.5)。
- D-二聚体与复发性缺血性卒中的HR为1.2(95% CI 1.0-1.5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with cancer and acute ischemic stroke (AIS) face high rates of recurrent thromboembolism or death. OBJECTIVES: To examine whether hematologic and embolic biomarkers soon after AIS are associated with subsequent adverse clinical outcomes. METHODS: We prospectively enrolled 50 adults with active solid tumor cancer and AIS at two hospitals from 2016 to 2020. Blood was collected 72-120 h after stroke onset. A 30-min transcranial Doppler (TCD) microemboli detection study was performed. The exposure variables were hematologic markers of coagulation (D-dimer, thrombin-antithrombin), platelet (P-selectin), and endothelial activation (thrombomodulin, soluble intercellular adhesion molecule-1 [sICAM-1], soluble vascular cell adhesion molecule-1 [sVCAM-1]), and the presence of TCD microemboli. The primary outcome was a composite of recurrent arterial/venous thromboembolism or death. We used Cox regression to evaluate associations between biomarkers and subsequent outcomes. RESULTS: During an estimated median follow-up time of 48 days (IQR, 18-312), 43 (86%) participants developed recurrent thromboembolism or death, including 28 (56%) with recurrent thromboembolism, of which 13 were recurrent AIS (26%). In unadjusted analysis, D-dimer (HR 1.6; 95% CI 1.2-2.0), P-selectin (HR 1.9; 95% CI 1.4-2.7), sICAM-1 (HR 2.2; 95% CI 1.6-3.1), sVCAM-1 (HR 1.6; 95% CI 1.2-2.1), and microemboli (HR 2.2; 95% CI 1.1-4.5) were associated with the primary outcome, whereas thrombin-antithrombin and thrombomodulin were not. D-dimer was the only marker associated with recurrent AIS (HR 1.2; 95% CI 1.0-1.5). Results were generally consistent in analyses adjusted for important prognostic variables. CONCLUSIONS: Markers of hypercoagulability and embolic disease may be associated with adverse clinical outcomes in cancer-related stroke.
引用
- Navi BB, Zhang C, Sherman CP, et al. Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes. J Thromb Haemost. 2022. PMID: 35652416. doi:10.1111/jth.15779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。